Biofrontera Inc. Cost of Revenue
Biofrontera Inc. (BFRI) reported Cost of Revenue of $41.00 thousand for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-30.
Discontinued › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2021-11-30
- Biofrontera Inc. cost of goods and services sold for the quarter ending 2021-09-30 was $41.00K, a 90.81% decline year-over-year.
- Biofrontera Inc. cost of goods and services sold for the quarter ending 2020-09-30 was $446.00K.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 9 month |
|---|---|---|
| 2021-09-30 | $41.00K 10-Q · filed 2021-11-30 | $339.00K 10-Q · filed 2021-11-30 |
| 2020-09-30 | $446.00K 10-Q · filed 2021-11-30 | $617.00K 10-Q · filed 2021-11-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B |